Gilead axes PhIII trial for CD47 drug in latest setback for $4.9B buyout
Gilead will scrap one of three Phase III trials for magrolimab, the anti-CD47 drug at the heart of its $4.9 billion acquisition of Forty Seven …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
